CN102227419A - Anhydrate and hydrate forms of strontium ranelate - Google Patents
Anhydrate and hydrate forms of strontium ranelate Download PDFInfo
- Publication number
- CN102227419A CN102227419A CN2009801474430A CN200980147443A CN102227419A CN 102227419 A CN102227419 A CN 102227419A CN 2009801474430 A CN2009801474430 A CN 2009801474430A CN 200980147443 A CN200980147443 A CN 200980147443A CN 102227419 A CN102227419 A CN 102227419A
- Authority
- CN
- China
- Prior art keywords
- strontium ranelate
- strontium
- ranelate
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940079488 strontium ranelate Drugs 0.000 title claims abstract description 191
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 title abstract description 153
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 51
- 239000013078 crystal Substances 0.000 claims description 40
- 150000004677 hydrates Chemical class 0.000 claims description 31
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 26
- 238000001035 drying Methods 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- DJSXNILVACEBLP-UHFFFAOYSA-N ranelic acid Chemical compound OC(=O)CN(CC(O)=O)C=1SC(C(O)=O)=C(CC(O)=O)C=1C#N DJSXNILVACEBLP-UHFFFAOYSA-N 0.000 claims description 20
- 229950003464 ranelic acid Drugs 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 19
- 239000003960 organic solvent Substances 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 12
- -1 strontium ranelate tetrahydrate Chemical class 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 claims description 10
- 238000006114 decarboxylation reaction Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 159000000008 strontium salts Chemical class 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 239000006227 byproduct Substances 0.000 claims description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003849 aromatic solvent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- ZHEZAQJNZMLYBA-UHFFFAOYSA-J distrontium;5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate;octahydrate Chemical compound O.O.O.O.O.O.O.O.[Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N ZHEZAQJNZMLYBA-UHFFFAOYSA-J 0.000 claims 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 150000004685 tetrahydrates Chemical group 0.000 description 15
- 150000004690 nonahydrates Chemical group 0.000 description 14
- 238000002329 infrared spectrum Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 229910052712 strontium Inorganic materials 0.000 description 9
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 238000001237 Raman spectrum Methods 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 150000004688 heptahydrates Chemical class 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000010025 steaming Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000003109 Karl Fischer titration Methods 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- FYGHSUNMUKGBRK-UHFFFAOYSA-N 1,2,3-trimethylbenzene Chemical compound CC1=CC=CC(C)=C1C FYGHSUNMUKGBRK-UHFFFAOYSA-N 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MXLMTQWGSQIYOW-UHFFFAOYSA-N methyl isopropyl carbinol Natural products CC(C)C(C)O MXLMTQWGSQIYOW-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- LMHHRCOWPQNFTF-UHFFFAOYSA-N s-propan-2-yl azepane-1-carbothioate Chemical compound CC(C)SC(=O)N1CCCCCC1 LMHHRCOWPQNFTF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- OHULXNKDWPTSBI-UHFFFAOYSA-N strontium;propan-2-olate Chemical compound [Sr+2].CC(C)[O-].CC(C)[O-] OHULXNKDWPTSBI-UHFFFAOYSA-N 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic System
Abstract
The present invention relates to novel anhydrate and hydrate forms of strontium ranelate, processes for the preparation thereof and a pharmaceutical composition comprising said strontium ranelate.
Description
The present invention relates to strontium ranelate (strontium ranelate), its preparation method of new anhydrous and hydrated form and contain the pharmaceutical composition of described strontium ranelate.In addition, the present invention relates to the by product that in the strontium ranelate of synthetic new form, obtains.
Strontium ranelate, its chemical name are 5-[two (carboxymethyl)-amino]-2-carboxyl-4-cyano group-3-thiophene acetic acid two strontium salt, chemical structural formula is as follows:
Strontium ranelate, two strontiums (II) salt for Ranelic acid is known as the medicine that is used for the treatment of osteoporosis, for example by Servier with
Or
Sell.Strontium ranelate comprises the bone seeker strontium.Think that it passes through the metabolic dual function of bone (increase bone forming and reduce bone resorption) is worked, thereby cause the balance again that helps osteoplastic bone renewal.Strontium ranelate has very valuable pharmacological character and therapeutic property, particularly has outstanding osteoporosis character, makes this compound be useful on the treatment osteopathia.
Strontium ranelate can freely be dissolved in the aqueous medium of low pH (＜pH 2), but only is slightly soluble in the neutral aqueous medium.Strontium ranelate is actual to be insoluble to most of organic solvents.
The strontium ranelate of more known crystallized forms in this area.EP 415 850 A1 disclose the strontium ranelate of eight hydrates, heptahydrate and tetrahydrate form.WO 2006/035122 A1 discloses the strontium ranelate of nonahydrate form.But the strontium ranelate of these known crystallized forms is hygroscopic, and is unsettled therefore, and this makes that preparation of drug combination is difficulty and disadvantageous.
Therefore, the strontium ranelate that needs a kind of form in the art, it does not demonstrate the problem of the strontium ranelate of form known, and is in particular non-hygroscopic, stable, yet have again enough water-soluble, water-soluble bigger than the strontium ranelate of form known particularly.
The strontium ranelate that has been found that the anhydrous and hydrated form of prior art problems can be by having reduction than form known water-content is at present overcome.In addition, also have been found that, the strontium ranelate of these forms can obtain by following steps: heating is suspended in the strontium ranelate in the organic solvent under refluxing, reclaim solid, strontium salt and Ranelic acid (ranelic acid) are reacted in some solvent, or dry under certain conditions strontium ranelate hydrate.Compare with the strontium ranelate of known crystallized form in this area, the water absorbability of the strontium ranelate of gained form is littler, more stable and easier to be molten.
Therefore, the strontium ranelate that the present invention relates to has the water-content less than about 5.5 weight %.Preferably, the water-content of the strontium ranelate of hydrated form is that about 1.5 weight % are to about 5.5 weight %.
Preferably, the water-content that the strontium ranelate of hydrated form of the present invention has is extremely about 4.5 weight % of about 2.5 weight %, is in particular about 3.3 weight % to about 3.5 weight %, 3.4 weight % according to appointment.Be known in the art several different methods and determine the water-content of chemical substance.These methods for example have Ka Er Karl Fischer titration (Karl-Fischer-titration) or " weight loss on drying (loss-on-drying) " to analyze (LOD, drying loss).For the present invention, determine that according to the Ka Er Karl Fischer titration water-content may be disadvantageous, because compound must be dissolved in the organic solvent fully.Therefore, the present invention preferably determines water-content according to weight loss on drying analysis (LOD).Weight loss on drying is the laboratory method of water-content level in a kind of known measurement solid or the semi-solid material, known this method of how carrying out in this area.Usually, the sample of the material of weighing is chosen wantonly in baking oven and is under reduced pressure heated the suitable time (for example, at 180 ℃, spending the night, at 30mbar), and cooling is chosen wantonly in the dry atmosphere of moisture eliminator (exsiccator) and cooled off, and then weighs.If this solid volatile matter inclusion mainly is a water, the LOD technology provides the measurement of good moisture content so.As used herein, the water-content of strontium ranelate is most preferably measured with LOD (180 ℃, 30mbar, 12 hours), that is, heating was above 12 hours under the pressure condition of 180 ℃ temperature and 30mbar.
In theory, the water-content of strontium ranelate semihydrate is about 1.7 weight %, and the water-content of strontium ranelate monohydrate is 3.4 weight %, and the water-content of strontium ranelate sesquialter hydrate is about 5 weight %.Therefore, all these forms includes within the scope of the invention.
Strontium ranelate of the present invention can be amorphous or crystallized form.The strontium ranelate of anhydrous form is preferably and is amorphous form.
The strontium ranelate of crystallization and amorphous form can be identified according to their X-ray powder diffraction pattern (XRD).(Bruker-AXS, Karlsruhe Germany) go up analytic sample at Bruker-axs D8 Advance powder x-ray diffraction instrument.During the measurement, sample fixer rotates with 20rpm in being parallel to its surperficial plane.Measuring condition is as follows: radioactive rays: Cu K α, radioactive source 40kV/40mA, divergent slit 0.6mm, anti-scatter slit 5.59mm, detector slit 10.28mm, 2 ° of start angles, 55 ° of angles at the end, 0.016 ° of 2 Θ of stepping (step).Raw data is by service routine EVA (Bruker-AXS, Karlsruhe, Germany) assessment.The additive method and the device of measured X ray powder diffraction pattern are well known in the art, and for example can be with reference to WO 2006/035122.
Strontium ranelate (crystal formation I) according to first crystallized form of the present invention preferably has significant X-ray powder diffraction pattern peak at place, following 2 θ angles: 17.6 ± 0.2,23.1 ± 0.2 and 27.5 ± 0.2, more preferably 12.6 ± 0.2,17.6 ± 0.2,23.1 ± 0.2 and 27.5 ± 0.2, particularly it has the most significant peak at place, following 2 θ angles: 8.7 ± 0.2,12.6 ± 0.2,17.6 ± 0.2,20.3 ± 0.2,23.1 ± 0.2,26.3 ± 0.2,27.5 ± 0.2 and 29.5 ± 0.2.
Preferably, the strontium ranelate of crystal formation I has the X-ray powder diffraction pattern, and wherein the peak is at place, following 2 θ angles and roughly have following relative intensity:
In one embodiment, has X-ray powder diffraction pattern according to the crystal formation I of strontium ranelate of the present invention corresponding to pattern shown in Figure 1.In another embodiment, the invention provides the strontium ranelate of solid-state structure, it is characterized in that X-ray powder diffraction pattern that this structure provides is corresponding to pattern shown in Figure 1.
Second crystallized form (crystal form II) according to strontium ranelate of the present invention preferably has significant X-ray powder diffraction pattern peak at place, following 2 θ angles: 8.7 ± 0.2,13.7 ± 0.2 and 17.5 ± 0.2, more preferably 8.7 ± 0.2,9.2 ± 0.2,13.7 ± 0.2 and 17.5 ± 0.2, particularly it has the most significant peak at place, following 2 θ angles: 8.7 ± 0.2,9.2 ± 0.2,10.4 ± 0.2,13.7 ± 0.2,17.5 ± 0.2,19.7 ± 0.2,25.5 ± 0.2 and 27.1 ± 0.2.
Preferably, the crystal form II of strontium ranelate has the X-ray powder diffraction pattern, and wherein the peak is located at following 2 θ angles, and roughly has following relative intensity:
| The angle | Relative intensity |
| 2θ°(±0.2) | ％ |
| 8.7 | 43.3 |
| 9.2 | 100.0 |
| 9.5 | 20.3 |
| 10.4 | 24.9 |
| 10.9 | 11.8 |
| 13.7 | 19.3 |
| 14.1 | 18.8 |
| 14.5 | 10.5 |
| 15.7 | 11.9 |
| 16.3 | 11.5 |
| 17.5 | 11.6 |
| 18.3 | 13.6 |
| 19.2 | 13.2 |
| 19.7 | 16.1 |
| 20.8 | 13.8 |
| 21.5 | 10.6 |
| 21.9 | 10.8 |
| 23.2 | 15.6 |
| 25.2 | 17.7 |
| 25.2 | 23.8 |
| 25.8 | 16.1 |
| 26.3 | 16.1 |
| 26.7 | 18.2 |
| 27.1 | 22.0 |
| 27.7 | 16.9 |
| 28.5 | 15.0 |
| 29.1 | 19.6 |
| 29.5 | 14.4 |
| 31.1 | 14.7 |
| 32.8 | 10.2 |
| 32.9 | 10.0 |
| 34.3 | 12.0 |
| 34.9 | 15.8 |
| 36.1 | 13.2 |
| 39.5 | 11.2 |
| 42.0 | 11.7 |
| 43.3 | 11.7 |
| 43.9 | 13.1 |
In one embodiment, has X-ray powder diffraction pattern according to the crystal form II of strontium ranelate of the present invention corresponding to pattern shown in Figure 2.In another embodiment, the invention provides the strontium ranelate of solid-state structure, it is characterized in that X-ray powder diffraction pattern that this structure provides is corresponding to pattern shown in Figure 2.
Strontium ranelate (crystal form II I) according to the 3rd crystallized form of the present invention preferably has significant X-ray powder diffraction pattern peak at place, following 2 θ angles: 10.5 ± 0.2,13.9 ± 0.2 and 19.7 ± 0.2, more preferably 9.2 ± 0.2,10.5 ± 0.2,13.9 ± 0.2 and 19.7 ± 0.2, particularly it has the most significant peak at place, following 2 θ angles: 9.2 ± 0.2,10.5 ± 0.2,13.9 ± 0.2,14.2 ± 0.2,19.7 ± 0.2,26.8 ± 0.2 and 27.2 ± 0.2.
Preferably, the crystal form II I of strontium ranelate has the X-ray powder diffraction pattern, and wherein the peak is located at following 2 θ angles, and roughly has following relative intensity:
| The angle | Relative intensity |
| 2θ°(±0.2) | ％ |
| 9.2 | 100.0 |
| 10.2 | 12.8 |
| 10.5 | 27.7 |
| 13.9 | 17.0 |
| 14.2 | 18.6 |
| 15.8 | 12.1 |
| 18.1 | 8.5 |
| 18.4 | 10.9 |
| 19.3 | 13.5 |
| 19.7 | 17.3 |
| 20.9 | 12.6 |
| 21.1 | 13.1 |
| 21.6 | 10.7 |
| 22.8 | 9.9 |
| 23.1 | 10.9 |
| 23.3 | 13.5 |
| 25.1 | 10.4 |
| 25.6 | 20.8 |
| 25.9 | 11.0 |
| 26.5 | 14.6 |
| 26.8 | 22.5 |
| 27.2 | 25.3 |
| 27.8 | 15.7 |
| 28.6 | 16.5 |
| 29.2 | 14.3 |
| 31.2 | 11.9 |
| 32.8 | 10.6 |
| 34.4 | 10.3 |
| 35.0 | 13.5 |
| 39.7 | 11.9 |
| 42.1 | 10.7 |
| 43.4 | 10.0 |
| 43.9 | 13.4 |
In one embodiment, has X-ray powder diffraction pattern according to the crystal form II I of strontium ranelate of the present invention corresponding to pattern shown in Figure 3.In another embodiment, the invention provides the strontium ranelate of solid-state structure, it is characterized in that X-ray powder diffraction pattern that this structure provides is corresponding to pattern shown in Figure 3.
The invention further relates to first method of the strontium ranelate of the aforesaid anhydrous or hydrated form of preparation, this method comprises the following steps:
A) rough strontium ranelate is suspended in the organic solvent, particularly in the toluene,
B) heating steps suspension a) under refluxing,
C) cool off this suspension,
D) reclaim this solid and dry this solid, obtain the strontium ranelate crystal, and
E) randomly the strontium ranelate of crystallized form is converted into the strontium ranelate of amorphous form.
Rough strontium ranelate as the step a) in the aforesaid method, can use various strontium ranelates, preferred known tetrahydrate, heptahydrate or eight hydrate forms, described in this area, for example described in EP 415 850 A1, or the nonahydrate of strontium ranelate, described in this area, for example described in WO 2006/035122 A1.
In step a), rough strontium ranelate is suspended in the organic solvent.Can use various suitable formation to contain the suspension of strontium ranelate and further be adapted at refluxing down and remove the organic solvent anhydrate.In one embodiment, organic solvent is an aromatic solvent, for example benzene, toluene, ethylbenzene, dimethylbenzene, trimethylbenzene, 1,2-dichlorobenzene or its mixture, preferred toluene or 1,2-dichlorobenzene.For example, can obtain strontium ranelate crystalline crystal formation I by using toluene, by using 1, the 2-dichlorobenzene can obtain amorphous strontium ranelate.
In second embodiment, organic solvent is non-proton property aliphatic solvent, for example hexanaphthene.In this embodiment, can obtain strontium ranelate crystalline crystal form II.
In the 3rd embodiment, organic solvent is the protic aliphatic solvent, for example alcohol, particularly methyl alcohol, ethanol, isopropylcarbinol and composition thereof, for example mixture of methyl alcohol and isopropylcarbinol.In this embodiment, can obtain strontium ranelate crystalline crystal form II I.
In step b), the suspension that heating steps obtains in a) under refluxing.The required temperature that fully refluxed depends on employed organic solvent.If use toluene as organic solvent, then suspension is heated to about 130 ℃ to guarantee sufficient backflow.If organic solvent is a hexanaphthene, then temperature can be about 140 ℃.If organic solvent is an ethanol, then temperature can be about 110 ℃.If Heating temperature is higher than the boiling point of solvent, then temperature is the temperature of heating unit such as heating bath.Randomly, can between the heating period of step b), add the organic solvent of additional quantity, preferably identical with the organic solvent that in step a), uses.
In step c), with the suspension cooling, preferably be cooled to room temperature, or below, for example to about 25 ℃, 20 ℃ or 4 ℃.
In step d), reclaim solid, and drying obtains strontium ranelate crystal of the present invention.Because strontium ranelate is dissolved in most of organic solvents hardly, therefore can realize the recovery of high yield.Preferably, the drying in the step d) is promptly carried out under vacuum in room temperature and at about 5mbar or lower pressure.
In another embodiment of the inventive method, in step d), dry about 30 ℃ to about 60 ℃, about 50 ℃ of extremely about 60 ℃ temperature and under about 5mbar or lower pressure, carrying out particularly.
In another embodiment of the inventive method, in step d), dry about 70 ℃ to about 90 ℃, about 80 ℃ temperature and carry out under the 1mbar according to appointment particularly at about 5mbar or lower pressure.
In an embodiment of the inventive method, the drying in the step d) about 30 ℃ to about 60 ℃, particularly about 50 ℃ carry out to about 60 ℃ temperature and under about 100mbar or lower pressure, preferably about 100mbar to 5mbar, particularly 50mbar to 5mbar.
Perhaps, the method preparation that strontium ranelate crystalline crystal form II can be by may further comprise the steps: about 130 ℃ to about 150 ℃, according to appointment 140 ℃ and under about constant pressure dry strontium ranelate eight hydrates or strontium ranelate tetrahydrate.
Perhaps, strontium ranelate crystalline crystal form II I can prepare by strontium salt, particularly Virahol strontium (strontium isopropoxide) and Ranelic acid are reacted in ethylene glycol.This reaction can for example be undertaken by following: stirring at room Virahol strontium and the Ranelic acid solution in ethylene glycol, for a long time, 72 hours according to appointment, and reclaim throw out.
Aforesaid method can be used for obtaining the strontium ranelate according to crystallization of the present invention and amorphous form.Also can for example prepare by methods known in the art according to amorphous strontium ranelate of the present invention, for example by cooling off the melts of strontium ranelate fast from strontium ranelate crystal according to the present invention.
Perhaps, the strontium ranelate of anhydrous amorphous form can by be higher than about 160 ℃, 180 ℃ temperature drying strontium ranelate hydrate prepares according to appointment.Drying can implement about 2 hours or more than, 3 hours to about 6 hours according to appointment.Drying can be carried out under constant pressure or decompression, according to appointment 30mbar or following.
The invention still further relates to the strontium ranelate of the hydrated form that can obtain by aforesaid method.
The invention still further relates to the pharmaceutical composition that comprises aforesaid strontium ranelate of the present invention.This pharmaceutical composition also comprises suitable pharmaceutically acceptable vehicle and/or assistant agent as known in the art.This pharmaceutical composition preferably is suitable for oral administration, and is in particular tablet or dragee (dragee), wafer (sachet), granule, sublingual tablet, capsule or any other oral dosage form as known in the art.Useful dosage can change as known in the art, can for for example every day about 0.2 to about 10g, as 2g dosage every day.
The invention still further relates to aforesaid strontium ranelate and be used for preparing the purposes of the medicine for the treatment of osteopathia, particularly osteoporosis.
Find in addition, if heating Ranelic acid or strontium ranelate for example in the method for the invention, can form the strontium salt of decarboxylation Ranelic acid and decarboxylation Ranelic acid, its by product for not expecting.The decarboxylation Ranelic acid has following structural formula:
Because strontium ranelate as active constituents of medicine, importantly confirms the amount of by product in final strontium ranelate of not expecting.In order to determine the amount of by product in strontium ranelate, the sample (probes) that needs by product is as standard.Therefore, the strontium salt of decarboxylation Ranelic acid and decarboxylation Ranelic acid has used preparation HPLC to separate.The invention provides these compounds as the standard (standard) of determining strontium ranelate purity.
Strontium ranelate according to crystallization of the present invention and amorphous form can advantageously obtain by the inventive method.The example of the method according to this invention can be referring to embodiment 1 to 5 and 11 to 19.In embodiment 1 to 3, the strontium ranelate of aforesaid crystallized form begins preparation from the strontium ranelate tetrahydrate, for example according to EP 415 850 A1 preparation, in embodiment 4 and 5, strontium ranelate obtains from strontium ranelate eight hydrates, for example prepares according to EP 415 850 A1.
Aforesaid strontium ranelate can be advantageously used in the pharmaceutical composition, because its water absorbability is less than known crystallized form.This can find out from embodiment 10, in embodiment 10, and the dynamic moisture adsorption of the water of strontium ranelate eight hydrate samples (dynamic vapour sorption), i.e. the desorb of water and absorption compared with strontium ranelate according to the present invention.Shown in embodiment 10, eight hydrates can easily be converted into tetrahydrate by reducing humidity, and can obtain heptahydrate and nonahydrate by follow-up increase humidity.In contrast, when reducing humidity, strontium ranelate of the present invention (it comprises for example monohydrate) only discharges the water less than its gross weight 2%.The water of strontium ranelate of the present invention when humidity increases absorbs also very low.Strontium ranelate of the present invention is when about 80% relative humidity, and the quality increase only is 2% of about gross weight.This shows that in the wide region of 0% to 80% relative humidity, strontium ranelate of the present invention is a quite stable.
Except going out the color stability in the relative humidity of wide region, strontium ranelate of the present invention particularly also has outstanding solvability in the water at aqueous medium.As can from embodiment 6 find out that with the strontium ranelate of known crystallized form, promptly tetrahydrate, nonahydrate and eight hydrates are compared, strontium ranelate of the present invention (called after " strontium ranelate monohydrate ") has shown good solvability.In addition, the saturated solvability of strontium ranelate of the present invention in water is higher than the solvability of the strontium ranelate (being tetrahydrate, eight hydrates and the nonahydrate of strontium ranelate) of known crystallized form in this area.
The strontium ranelate of crystallized form can be identified by XRD measurement, Raman and infrared spectra, shown in embodiment 7 to 9.
Fig. 1 shows the X-ray powder diffraction pattern of strontium ranelate crystal formation I.
Fig. 2 shows the X-ray powder diffraction pattern of strontium ranelate crystal form II.
Fig. 3 shows the X-ray powder diffraction pattern of strontium ranelate crystal form II I.
Fig. 4 shows the stacking diagram of the Raman spectrum of five strontium ranelate samples, wherein is from bottom to up: 1: the strontium ranelate of embodiment 1; 2: the strontium ranelate of embodiment 2; 3: the strontium ranelate tetrahydrate prepares according to EP 415 850 A1; 4: the strontium ranelate nonahydrate obtains from strontium ranelate eight hydrates (according to EP 415 850 A1 preparation) according to the embodiment 1 of WO 2006/035122 A1; 5: eight hydrates (according to EP 415 850 A1 preparation).
Fig. 5 shows the infrared spectra of strontium ranelate crystal formation I.
Fig. 6 shows the dynamic moisture adsorption figure (being described in detail among the embodiment 10 of figure provides) of strontium ranelate eight hydrates (left side) and strontium ranelate of the present invention (right side).
Fig. 7 shows the infrared spectra of strontium ranelate crystal form II.
Fig. 8 shows the infrared spectra of strontium ranelate crystal form II I.
Further explain the present invention by following routine embodiment now.
Embodiment 1: the preparation of strontium ranelate
Weighing 2.0g strontium ranelate tetrahydrate (for example according to EP 415 850 A1 preparation) also is suspended in the 35ml toluene.Suspension is heated to 130 ℃.After some toluene are collected in the water separator, add extra 10ml toluene.Using water separator further to heat this suspension under refluxing spends the night.Reaction mixture is cooled to room temperature, and isolates white solid.Solid 5ml toluene wash, and in room temperature vacuum-drying.
Output: 1.58g
Analyze: XRD (being shown among Fig. 1), IR (among Fig. 2 figure below); LOD:3.0% (180 ℃, 30mbar spends the night).
Embodiment 2: the preparation of strontium ranelate
As described in embodiment 1, repeat to prepare strontium ranelate.
XRD is identical with the XRD of embodiment 1.IR spectrum is shown in Fig. 2 (from following several the 2nd figure); LOD:4.3% (180 ℃, 30mbar spends the night).
Embodiment 3: the preparation of strontium ranelate
Weighing 14.8g strontium ranelate tetrahydrate (for example according to EP 415 850 A1 preparation) also is suspended in the 300ml toluene.Suspension is heated to 130 ℃.After some toluene are collected in the water separator, add extra 50ml toluene.Using water separator further to heat this suspension under refluxing spends the night.Reaction mixture is cooled to room temperature, and isolates white solid.At 50 ℃ of these solids of vacuum-drying.
Output: 12.8g
Analyze: XRD (identical), LOD:3.9% (180 ℃, 30mbar spends the night) with embodiment 1.
Embodiment 4: the preparation of strontium ranelate
Weighing 75g strontium ranelate eight hydrates (for example according to EP 415 850 A1 preparation) also are suspended in the 1250ml toluene.Using water separator that suspension is heated to 130 ℃ under refluxing spends the night.Reaction mixture is cooled to room temperature, and isolates white solid.In kiln in 60 ℃ at the 50mbar drying solid.
Output: 62.5g
Analyze: XRD (identical), LOD:3.6% (180 ℃, 30mbar spends the night) with embodiment 1.
Embodiment 5: the preparation of strontium ranelate
Weighing 100g strontium ranelate eight hydrates (according to EP 415 850 A1 preparation) also are suspended in the 1400ml toluene.Using water separator that suspension is heated to 130 ℃ under refluxing spends the night.Reaction mixture is cooled to room temperature, and isolates white solid.In kiln in 60 ℃ at the 50mbar drying solid.
Output: 79.96g
Analyze: XRD (identical), LOD:4.6% (180 ℃, 30mbar spends the night) (solvent that contains residual content) with embodiment 1.
The summary of embodiment 1 to 5
The amount of initial composition, acquisition output and the surplus water of being determined by LOD (180 ℃, 30mbar spends the night) are summarised in the following table:
Embodiment 6: the stripping of strontium ranelate
Use following parameters to dissolve strontium ranelate of the present invention:
From top result as can be seen, compare with tetrahydrate, nonahydrate or eight crystal of hydrate forms, strontium ranelate of the present invention (called after " strontium ranelate monohydrate ") demonstrates improved stripping character, particularly after 60,90 and 120 minutes.
The saturated solvability of strontium ranelate in water determined 37 ℃ temperature.Deliquescently determine to finish by UV and HPLC method.The result is summarised in the following table:
From top form as can be seen, the solvability of strontium ranelate of the present invention (called after " strontium ranelate monohydrate ") has significant improvement than the solvability of the strontium ranelate of known tetrahydrate, eight hydrates and nonahydrate crystallized form.
Embodiment 7: the XRD of the strontium ranelate that embodiment 1 obtains
Determine the X-ray powder diffraction pattern of the strontium ranelate that embodiment 1 obtains, be shown among Fig. 1.
Following table has been summed up significant peak (significant peak):
The most significant reflection (significant reflexes) is 8.7,12.6,17.6,20.3,23.1,26.3,27.5 and 29.5 ° of 2 θ (the most characteristic peak is 17.6,23.1 and 27.5).
Embodiment 8: the Raman spectrum of the strontium ranelate of crystallized form
Obtained the Raman spectrum of 5 strontium ranelate samples, be shown among Fig. 4 with stacked system.Fig. 4 has shown following Raman spectrum from bottom to up: 1: the strontium ranelate of embodiment 1; 2: the strontium ranelate of embodiment 2; 3: strontium ranelate tetrahydrate (for example according to EP 415 850 A1 preparation); 4: nonahydrate obtains from strontium ranelate eight hydrates (for example according to EP 415 850 A1 preparation) according to the embodiment 1 of WO 2006/035122 A1; 5: strontium ranelate eight hydrates (for example according to EP 415 850 A1 preparation).
The spectrum that obtains from eight hydrates and nonahydrate is equal to.The spectrum demonstration that obtains from tetrahydrate highly conforms to the spectrum of eight hydrates and nonahydrate.1380cm
-1The peak at place is that tetrahydrate is distinctive.
The spectrum of the strontium ranelate that obtains from embodiment 1 and 2 and the difference of tetrahydrate, eight hydrates and nonahydrate are at least at about 1570cm
-1With about 1330cm
-1The peak that the place exists.
Embodiment 9: infrared spectra
The infrared spectra of the strontium ranelate that record embodiment 1 obtains also is shown among Fig. 5.
Opposite with the infrared spectra (being tetrahydrate, eight hydrates and nonahydrate (infrared spectra is not shown)) of the strontium ranelate of known crystallized form, the strontium ranelate of crystallized form of the present invention is at about 3200cm
-1The place does not show broad peak (OH-peak).In addition, significant difference also is 2200cm
-1Scope.In eight hydrates at about 2203cm
-1The peak that exists, tetrahydrate are typically about 2193 and about 2210cm
-1The place demonstrates bimodal.Strontium ranelate of the present invention about 2207 to about 2212cm
-1Demonstrate significant peak.
In addition, the difference between the strontium ranelate of known crystallized form and the strontium ranelate of the present invention can be about 1650 to about 1500cm
-1Scope observe.Especially, strontium ranelate of the present invention is about 1622,1555,1538 and 1508cm
-1The place has shown four characteristic peaks.In contrast to this, the infrared spectra of eight hydrates and nonahydrate only shows that (eight hydrates are 1551 and 1516cm at two significant peaks
-1The place; Tetrahydrate is 1567 and 1515cm
-1The place).
Embodiment 10: dynamic moisture adsorption
The desorb and the absorption of the water of the sample of assessment strontium ranelate eight hydrates and strontium ranelate of the present invention.25 ℃ temperature, change relative humidity with 5% speed per hour.0% minimum humidity and 95% maximal humidity kept respectively 3 hours.Detailed the results are shown among Fig. 6.
Following the carrying out of this dynamic moisture adsorption experiment is by being exposed to sample under the relative humidity of change.During beginning, relative humidity is 50%, is reduced to then near 0%, is increased to for 95% (V-characteristic by corresponding right side scale is represented) then.Simultaneously, determine the mass discrepancy (the U-shaped curve among the left figure since 100%, and the flatter curve among the right figure, also is the left side scale since 100%, two width of cloth figure) of sample.
The absorption figure of eight hydrates (the left figure of Fig. 6) shows that since eight hydrates, water is removed along with humidity reduces, and through the intermediate heptahydrate, obtains tetrahydrate.Increase with work humidity, tetrahydrate is converted into nonahydrate very fast.
Reduce to form with humidity and correlatedly to be, strontium ranelate of the present invention (being shown among the right figure of Fig. 6) only discharges the water less than its gross weight 2%.Along with humidity increases, water absorbs also very slow.In about 80% humidity, the weight increase only is 2% of about gross weight.This is presented between 0% to 80% relative humidity, and strontium ranelate of the present invention is highly stable.
Embodiment 11: use hexanaphthene to prepare crystal form II
Add the 30ml hexanaphthene in 530mg in the 50ml round-bottomed flask (0.81mmol) strontium ranelate eight hydrates.Use water separator in oil bath in 140 ℃ of this mixtures 5 hours of refluxing.After being cooled to room temperature, leaching product, and use hexane wash.Revolving on the steaming device in 60 ℃ of dryings 3 hours.
DSC:173,107 ℃ (being heat absorption)
Embodiment 12: prepare crystal form II by drying
Weighing 2.00g (3.42mmol) strontium ranelate tetrahydrate (internal diameter: 45mm), and of packing in the 20ml LOD bottle normal atmosphere and 140 ℃ of dryings 3 hours.
DSC:173,107 ℃ (being heat absorption)
Embodiment 13: use ethanol preparation crystal form II I
Add 100ml ethanol in 4.0g (6.09mmol) strontium ranelate eight hydrates in 500ml two neck round-bottomed flasks.Water distilling apparatus is connected to a neck, under atmospheric pressure uses oil bath (bathing 110 ℃ of temperature) to distill out volatile matter.Distill after 45 minutes, add 150ml ethanol again, and continue distillation 45 minutes again, and then add 150ml ethanol.Continuing distillation is retained in the flask up to dried residue.Amount to 12 hours in 80 ℃/1mbar drying.
DSC:161,112 ℃ (being heat absorption)
Embodiment 14: the amplification test in proportion that uses ethanol preparation crystal form II I
Add 1500ml ethanol in 27.0g (0.041mol) strontium ranelate eight hydrates in 2l two neck round-bottomed flasks.Water distilling apparatus is connected to a neck, and mechanical stirrer is connected to another neck.Under atmospheric pressure use oil bath (110 ℃) to distill out volatile matter.Distill after 8 hours, add 500ml ethanol again, and continue distillation 5 hours again.Add 500ml ethanol again, and continue distillation 6 hours.From reaction mixture, take out equal portions (an aliquot), and on outstanding steaming device dry (60 ℃, 1mbar, 2 hours).The DSC of this sample is equal to the DSC of required crystal formation.In 60 ℃ of these reaction mixtures of vacuum concentration.Product is transferred to dry spray gun, and amounts to 8 hours in 60 ℃/1mbar drying.
DSC:161,112 ℃ (being heat absorption)
Embodiment 15: use methyl alcohol/isopropylcarbinol to prepare crystal form II I
Add 100ml methyl alcohol in 2.5g in the 500ml round-bottomed flask (3.80mmol) strontium ranelate eight hydrates.With this suspension returning 3 hours, add the 100ml isopropylcarbinol afterwards.In outstanding steaming device, remove volatile matter in 60 ℃.60 ℃/1mbar desciccate 2 hours, then 80 ℃/1mbar desciccate 1 hour.
DSC:165,110 ℃ (being heat absorption)
Embodiment 16: begin to prepare crystal form II I from the Virahol strontium
Being dissolved in 96mg (0.28mmol) Ranelic acid in the 10ml ethylene glycol in the 50ml round-bottomed flask adds the solution of 114mg (0.56mmol) Virahol strontium in 5ml ethylene glycol.The initial clear soln of stirring at room 72 hours.Make the milky white throw out sedimentation of formation, and remove supernatant liquor with transfer pipet.Throw out is pulp again in the 15ml methylene dichloride, and sedimentation is also removed supernatant liquor with transfer pipet.Repeating this washing becomes thinner and easily come off (flakier) up to throw out.Filter this throw out, use washed with dichloromethane, and (60 ℃/1mbar) went up dry 3 hours of outstanding steaming devices.
Embodiment 17: prepare amorphous strontium ranelate
Strontium ranelate eight hydrates of 252mg are suspended in 1, in the 2-two chloro-benzene.At 240 ℃ of this mixtures 2 hours of refluxing.Leach product, and 60 ℃ of dryings 3 hours.The DSC of product shows metamict, and does not have the typical peaks of crystalline state.
Embodiment 18: prepare amorphous strontium ranelate
With 0.5mmol Virahol strontium (strontium isopropylate) [Sr (OiPr)
2] be dissolved in the methyl alcohol of backflow.In this solution, add the 1.2mmol Ranelic acid, stirred this mixture 1 hour at reflux temperature.Collect solid sediment, and 60 ℃ of dryings 1 hour.
Repeat previous experiment, the dissolving Ranelic acid adds the Virahol strontium subsequently earlier.
Embodiment 19: preparation decarboxylation Ranelic acid
In the 100ml round-bottomed flask, 2g strontium ranelate eight hydrates are suspended in the 40ml toluene.Use water separator suspension to be stirred 5 days, filter then in 145 ℃.With 5-10ml toluene wash solid and dry 2 hours at 50 ℃/45mbar.Solid is dissolved in the water, and with pH regulator to 1.Water evaporates organic phase with ethyl acetate (2x 15ml) extraction.Residuum is dissolved in the water again, and concentration is about 1g/10ml, uses preparation HPLC to separate title compound.1H?NMR：δ＝3.56(s，2H，CH2)，4.36(s，4H，NCH2)，6.46(s，1H，CH)ppm.HPLC-MS：299.1(M+)。
Claims (28)
1. strontium ranelate, its water-content is less than about 5.5 weight %.
2. according to the strontium ranelate of claim 1, its water-content is that about 1.5 weight % are to about 5.5 weight %.
3. according to the strontium ranelate of claim 1 or 2, it is an amorphous form.
4. according to the strontium ranelate of claim 2, it is a crystallized form.
5. according to the crystal formation I of the strontium ranelate of claim 4, the place has significant X-ray powder diffraction pattern peak at following 2 θ angles: 12.6 ± 0.2,17.6 ± 0.2,23.1 ± 0.2 and 27.5 ± 0.2.
6. according to the crystal formation I of the strontium ranelate of claim 4 or 5, has X-ray powder diffraction pattern corresponding to pattern shown in Figure 1.
7. according to the crystal form II of the strontium ranelate of claim 4, the place has significant X-ray powder diffraction pattern peak at following 2 θ angles: 8.7 ± 0.2,13.7 ± 0.2 and 17.5 ± 0.2.
8. according to the crystal form II of the strontium ranelate of claim 4 or 7, has X-ray powder diffraction pattern corresponding to pattern shown in Figure 2.
9. according to the crystal form II I of the strontium ranelate of claim 4, the place has significant X-ray powder diffraction pattern peak at following 2 θ angles: 10.5 ± 0.2,13.9 ± 0.2 and 19.7 ± 0.2.
10. according to the crystal form II I of the strontium ranelate of claim 4 or 9, has X-ray powder diffraction pattern corresponding to pattern shown in Figure 3.
11. according to the strontium ranelate of the amorphous form of claim 3, it is anhydrous.
12. prepare the method for the strontium ranelate of anhydrous or hydrated form, it comprises the following steps:
A) rough strontium ranelate is suspended in the organic solvent,
B) heating steps suspension a) under refluxing,
C) cool off this suspension,
D) reclaim this solid and dry this solid, obtain the strontium ranelate crystal, and
E) randomly the strontium ranelate of crystallized form is converted into the strontium ranelate of amorphous form.
13. according to the method for claim 12, wherein said organic solvent is an aromatic solvent, as toluene or 1, and the 2-dichlorobenzene, non-proton property aliphatic solvent, as hexanaphthene, or the protic aliphatic solvent, as alcohol.
14. according to the method for claim 12 or 13, wherein the drying in the step d) is carried out in room temperature and under about 5mbar or lower pressure.
15. according to each method in claim 12 or 13, wherein the drying in the step d) is at about 30 ℃ to about 60 ℃ and carry out under about 100mbar or lower pressure.
16. according to the method for claim 15, wherein said drying is carried out under about 5mbar or lower pressure.
17. according to each method in claim 12 or 13, wherein the drying in the step d) is at about 70 ℃ to about 90 ℃ and carry out under about 5mbar or lower pressure.
18. the method for crystal form II of preparation strontium ranelate, described method be included in about 130 ℃ to about 150 ℃ temperature and under about constant pressure the step of dry strontium ranelate eight hydrates or strontium ranelate tetrahydrate.
19. the method for crystal form II I of preparation strontium ranelate, described method comprise the step that strontium salt and Ranelic acid are reacted in ethylene glycol.
20. the method for the strontium ranelate of preparation anhydrous form, described method is included in the step that is higher than about 160 ℃ temperature drying strontium ranelate hydrate.
21. the strontium ranelate of hydrated form, it can obtain by each method in the claim 12 to 19.
22. the strontium ranelate of anhydrous form, it can obtain by the method for claim 20.
23. the strontium ranelate of solid-state structure is characterized in that X-ray powder diffraction pattern that this structure provides is corresponding to Fig. 1,2 or 3 patterns that show.
24. pharmaceutical composition, it comprises according to each strontium ranelate and suitable pharmaceutically acceptable vehicle and/or assistant agent in claim 1 to 11 or 21 to 23.
25. be used for the treatment of purposes in the medicine of osteoporosis in preparation according to each strontium ranelate in claim 1 to 11 or 21 to 23.
26. the decarboxylation Ranelic acid of following formula:
27. strontium salt according to the decarboxylation Ranelic acid of claim 26.
28. according to the decarboxylation Ranelic acid of claim 26 or be used for determining the purposes of strontium ranelate amount of by-products as standard according to the strontium salt of the decarboxylation Ranelic acid of claim 27.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08017141 | 2008-09-29 | ||
| EP08017141.6 | 2008-09-29 | ||
| IN593/CHE/2009 | 2009-03-16 | ||
| IN593CH2009 | 2009-03-16 | ||
| PCT/EP2009/062439 WO2010034806A1 (en) | 2008-09-29 | 2009-09-25 | Anhydrate and hydrate forms of strontium ranelate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102227419A true CN102227419A (en) | 2011-10-26 |
Family
ID=41394902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801474430A Pending CN102227419A (en) | 2008-09-29 | 2009-09-25 | Anhydrate and hydrate forms of strontium ranelate |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2346846A1 (en) |
| KR (1) | KR20110066197A (en) |
| CN (1) | CN102227419A (en) |
| IL (1) | IL212024A0 (en) |
| RU (1) | RU2011116926A (en) |
| WO (1) | WO2010034806A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102764235A (en) * | 2012-06-21 | 2012-11-07 | 浙江华海药业股份有限公司 | Strontium ranelate dry suspension and preparation method thereof |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1398542B1 (en) * | 2010-03-05 | 2013-03-01 | Chemelectiva S R L | PROCESS FOR THE PREPARATION OF A POLIMORFO |
| WO2012046251A2 (en) * | 2010-10-08 | 2012-04-12 | Glenmark Generics Limited | Novel form of ranelic acid |
| WO2012143932A1 (en) * | 2011-04-21 | 2012-10-26 | Shilpa Medicare Limited | Crystalline strontium ranelate form-s |
| CZ2011320A3 (en) | 2011-05-30 | 2012-12-12 | Zentiva, K.S. | Stable crystalline form of X strontium renelate |
| CN102321068B (en) * | 2011-08-01 | 2013-01-23 | 山东铂源药业有限公司 | Method for preparing strontium ranelate |
| EP2641905A1 (en) | 2012-03-23 | 2013-09-25 | Urquima S.A. | Solid forms of strontium ranelate and processes for their preparation |
| US8569514B1 (en) | 2012-05-17 | 2013-10-29 | Divi's Laboratories, Ltd. | Process for the preparation of strontium ranelate |
| WO2013175270A1 (en) * | 2012-05-25 | 2013-11-28 | Fleming Laboratories Limited | Improved process for the preparation of strontium ranelate hydrates and new polymorphic form of monohydrate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2651497B1 (en) | 1989-09-01 | 1991-10-25 | Adir | NOVEL SALTS OF BIVALENT METALS OF N, N-DI ACID (CARBOXYMETHYL) AMINO-2 CYANO-3 CARBOXYMETHYL-4 CARBOXY-5 THIOPHENE, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| FR2875807B1 (en) | 2004-09-30 | 2006-11-17 | Servier Lab | ALPHA CRYSTALLINE FORM OF STRONTIUM RANELATE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| FR2921367B1 (en) * | 2007-09-26 | 2009-10-30 | Servier Lab | NEW PROCESS FOR THE SYNTHESIS OF STRONTIUM RANELATE AND ITS HYDRATES |
-
2009
- 2009-09-25 RU RU2011116926/04A patent/RU2011116926A/en not_active Application Discontinuation
- 2009-09-25 WO PCT/EP2009/062439 patent/WO2010034806A1/en active Application Filing
- 2009-09-25 CN CN2009801474430A patent/CN102227419A/en active Pending
- 2009-09-25 KR KR1020117009675A patent/KR20110066197A/en not_active Application Discontinuation
- 2009-09-25 EP EP09783416A patent/EP2346846A1/en not_active Withdrawn
-
2011
- 2011-03-29 IL IL212024A patent/IL212024A0/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102764235A (en) * | 2012-06-21 | 2012-11-07 | 浙江华海药业股份有限公司 | Strontium ranelate dry suspension and preparation method thereof |
| CN102764235B (en) * | 2012-06-21 | 2017-09-05 | 浙江华海药业股份有限公司 | Strontium ranelate dry suspension and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110066197A (en) | 2011-06-16 |
| EP2346846A1 (en) | 2011-07-27 |
| IL212024A0 (en) | 2011-06-30 |
| WO2010034806A1 (en) | 2010-04-01 |
| RU2011116926A (en) | 2012-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102227419A (en) | Anhydrate and hydrate forms of strontium ranelate | |
| KR102254062B1 (en) | Trisodium Valsartan: the solid form of sacubitril | |
| EP2985277B1 (en) | Method for preparing an atropisomer of a pyrrole derivative | |
| CN102046175A (en) | Substituted heterocycle fused gamma-carbolines solid | |
| EP3148979B1 (en) | Process for preparation of canagliflozin | |
| CN101939287B (en) | Crystalline modifications of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl -propyl)-phenol | |
| HUE027545T2 (en) | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate | |
| WO2006097624A1 (en) | 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof | |
| US20080027223A1 (en) | Polymorphs of eszopiclone malate | |
| RU2648990C1 (en) | Lobaplatin crystals, methods of production and applications in pharmaceuticals | |
| CN102659722A (en) | Amorphous cabazitaxel and preparation method thereof | |
| US9169257B2 (en) | Crystal forms of adefovir dipivoxil and processes for preparing the same | |
| CN113004244A (en) | Trelagliptin impurity and preparation method and application thereof | |
| US11566000B2 (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| CN101437791A (en) | Crystalline form of atorvastatin calcium stable after storage | |
| KR20220012821A (en) | Polymorphs of double acting compound and preparation method thereof | |
| CN110582279B (en) | Co-crystals of 2- (6-methyl-pyridin-2-yl) -3-yl- [ 6-amido-quinolin-4-yl ] -5, 6-dihydro-4H-pyrrolo [1,2-b ] pyrazole, methods for preparing the same and pharmaceutical compositions | |
| CN111793017A (en) | Preparation method of lactam compound | |
| JP2022520629A (en) | FGFR inhibitor compound in solid form and method for producing the same | |
| CN115925650B (en) | Epalrestat eutectic and preparation method and application thereof | |
| CN115197119B (en) | Preparation method of 6,6-dimethyl-3-azabicyclo [3.1.0] hexane-2, 4-dione | |
| CN108409691A (en) | A kind of Cabazitaxel crystal form HDC-1 and preparation method thereof | |
| AU2018201013B2 (en) | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride | |
| CN102020602B (en) | Crystal form of lercanidipine hydrochloride and preparation method thereof and crystal form-containing medicinal composition | |
| WO2016128760A1 (en) | New polymorphic forms of minocycline base and processes for their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111026 |